Cancer Research AACR Conference on Molecular Diagnostics - 2008  Translational Medicine Conference in Israel
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 53, 5714-5720, December 1, 1993]
© 1993 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, H.
Right arrow Articles by Johns, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, H.
Right arrow Articles by Johns, D. G.

Resistance to Cyclopentenylcytosine in Murine Leukemia L1210 Cells

Hao Zhang1, David A. Cooney, Ming H. Zhang, Gurpreet Ahluwalia, Harry Ford, Jr. and David G. Johns

Laboratory of Medicinal Chemistry, Developmental Therapeutics Program, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland 20892

1 To whom requests for reprints should be addressed, at Bldg. 37, Rm. 5B22, National Cancer Institute, NIH, Bethesda, MD 20892.

Cyclopentenyl cytosine (CPEC) exhibits oncological activity in murine and human tumor cells and has now entered Phase I clinical trials. Its mode of action as an antitumor agent appears to be inhibition by its triphosphate (CPEC-TP) of CTP synthase, the enzyme which converts UTP to CTP. In an attempt to elucidate the mechanism of resistance to CPEC, a murine leukemia cell line resistant to CPEC (L1210/CPEC) was developed by N-methyl-N-nitro-N-nitrosoguanidine-induced mutagenesis and subsequent selection by cultivation of the L1210 cells in the presence of 2 µM CPEC. Resistant clones were maintained in CPEC-free medium for 6 generations before biochemical studies were performed. The resistant clone selected for further studies was ~13,000-fold less sensitive to growth inhibition by CPEC than the parental cells, and the concentration of CPEC required to deplete CTP in the resistant cells was 50-fold higher than in the sensitive cells.

A comparison of the kinetic properties of CTP synthase from sensitive and resistant cells indicated alteration in the properties of the enzyme from the latter; the median inhibitory concentration for CPEC-TP increased from 2 to 14 µM, Km for UTP decreased from 126 to 50 µM, and Vmax increased 12-fold from 0.2 to 2.3 nmol/mg/min. Northern blot analyses of polyadenylated RNA from the resistant and sensitive cells indicated a 3-fold increase in transcripts of the CTP synthase gene in the resistant line. Consistent with these alterations in the properties of the enzyme, the resistant cells exhibited significantly expanded CTP and dCTP pools (4–5-fold) when compared with the sensitive cells. No change was observed, however, in the properties of uridine-cytidine kinase, the enzyme responsible for the initial phosphorylation of CPEC; despite this, however, cellular uptake of CPEC was greatly decreased, and phosphorylation of CPEC and its incorporation into RNA were 10-fold less than in the parental cells. These latter observations are most readily explained by feedback inhibition by the increased CTP levels of the resistant cells of uridinecytidine kinase and/or of the membrane transport process used for initial entry of CPEC.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 9/ 2/92. Accepted 9/30/93.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
Y.-F. Chang, S. S. Martin, E. P. Baldwin, and G. M. Carman
Phosphorylation of Human CTP Synthetase 1 by Protein Kinase C: IDENTIFICATION OF Ser462 AND Thr455 AS MAJOR SITES OF PHOSPHORYLATION
J. Biol. Chem., June 15, 2007; 282(24): 17613 - 17622.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M.-G. Choi and G. M. Carman
Phosphorylation of Human CTP Synthetase 1 by Protein Kinase A: IDENTIFICATION OF Thr455 AS A MAJOR SITE OF PHOSPHORYLATION
J. Biol. Chem., February 23, 2007; 282(8): 5367 - 5377.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. B. Ostrander, D. J. O'Brien, J. A. Gorman, and G. M. Carman
Effect of CTP Synthetase Regulation by CTP on Phospholipid Synthesis in Saccharomyces cerevisiae
J. Biol. Chem., July 24, 1998; 273(30): 18992 - 19001.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. M. Hatch and G. McClarty
Regulation of Cardiolipin Biosynthesis in H9c2 Cardiac Myoblasts by Cytidine 5'-Triphosphate
J. Biol. Chem., October 18, 1996; 271(42): 25810 - 25816.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. L. Wylie, L. L. Wang, G. Tipples, and G. McClarty
A Single Point Mutation in CTP Synthetase of Chlamydia trachomatis Confers Resistance to Cyclopentenyl Cytosine
J. Biol. Chem., June 28, 1996; 271(26): 15393 - 15400.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1993 by the American Association for Cancer Research.